On Friday, Shares of Innoviva Inc (NASDAQ:INVA), subtract -1.36% and shut at $10.91 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $10.66 and $11.05. The business’ commercial center capitalization is $1.16 Billion with the aggregate fabulous loads of 109.54 million. Innoviva Inc. (INVA) will replace Rofin-Sinar Technologies Inc. (RSTI) in the S&P SmallCap 600 after the close of trading on Wednesday, November 9. S&P SmallCap 600 constituent Coherent Inc. (COHR) attained Rofin-Sinar Technologies in a deal accomplished recently.
Innoviva engages in the development and commercialization of bio-pharmaceuticals. Headquartered in South San Francisco, CA, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Pharmaceuticals Sub-Industry index.
Shares of bluebird bio Inc (NASDAQ:BLUE), added 0.57% and shut at $62.00 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $61.10 and $63.17. The association’s commercial center capitalization is $2.33 Billion with the general uncommon loads of 37.30 million. bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, declared that interim data from its study of bb2121, the company’s anti-BCMA CAR T cell therapy, presently in a Phase 1 trial of patients with relapsed/refractory multiple myeloma will be presented at the EORTC-NCI-AACR Molecular Targets and Cancer Therapies Symposium in Munich, Germany.
Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma
Date: Thursday, December 1, 2016, 17:40 CET (11:40 am ET)
Session: Plenary Session 7